Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
An established treatment option for your ROS1+ and ALK+ advanced NSCLC patients.
Dosing and monitoring requirements for XALKORI
Clinical trial results including efficacy and safety outcomes
Important safety information
XALKORI as a monotherapy is indicated for:1
As a distinct molecular target in NSCLC5, ROS1 should be a reflex biomarker test alongside EGFR and ALK.2,3 XALKORI offers a potential median OS>4 years in ROS1+ advanced NSCLC patients, as demonstrated in the PROFILE 1001 study.6
KOL video resources, including best practices for ROS1 testing, tissue sample acquisition and the optimal model for molecular testing in patients with ROS1.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020